

Completion of the geneType™ commercial capability integration

Highlights

- ✓ **Completion of a significant proportion of the Genetype integration with the restoration of the commercial processes required to provide and sell geneType™.**
- ✓ **Integration activities include transfer of key personnel, re-establishment of critical supply partnerships, commercial infrastructure and transfer of highly valuable patient clinical data.**
- ✓ **Full integration is expected to be completed before the end of February, with a major focus on the future commercial opportunities for both the ColoSTAT® and geneType™ platforms.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) has completed the initial integration of the Genetype business following its acquisition on December 24, 2024. While initially projected to take over 12 weeks, Rhythm has fully transitioned all commercial operations and can now offer the complete geneType™ product portfolio (see www.genetype.com).

The transition involved the transfer, restoration and rebuilding of several processes and partnerships to allow the Company to offer commercial services of a similar or greater quality than previously offered. geneType™ is designed to provide assessment of risk for a range of diseases for individuals without other recognisable risk factors and as such, is suitable for a substantial global population. The Company is currently refining a commercial plan to capitalise on this opportunity.

Key Personnel

The complexity and unique nature of the algorithms linked to geneType™ requires highly specialised human capabilities and all the required staff critical to the support and future development of the geneType™ product portfolio have joined Rhythm continuing their employment based either in Australia or the USA.

Product Delivery Strategic Partners

Provision of the geneType™ test results requires the completion of patient sample acquisition and processing, DNA extraction and sequencing, bioinformatic analysis and interpretation and patient reporting. As such, the process requires several critical partners. Re-establishing agreements with Nest and DNAnexus was an important step in integrating geneType™ into Rhythm, allowing the team to focus their attention on driving adoption of geneType™ by health care professionals (HCPs) and their patients.

Nest Genomics is a software solution that makes it easy to offer genomic services and platforms like geneType™. By streamlining patient identification, clinical decision support, and tailored education for both HCPs and patients, Nest simplifies the process, enabling organisations to seamlessly implement and scale precision medicine.

DNAexus has built one of the world's most secure cloud platform and global network. The company's platform enables Genetype to easily manage, analyse, and collaborate on multimodal data, a critical component of ensuring accurate and timely reporting of risk assessment results for patients.

Transactional Processes

Much of the previous transactional infrastructure had been somewhat dissembled as a result of Genetic Technologies (GTG), the previous owner of geneType™, entering voluntary administration. As such, Rhythm has rebuilt the end-to-end customer engagement, reporting and billing processes for both the domestic and US markets.

Permits and Licences

The geneType™ product portfolio is regulated by several agencies and the team has transferred all the relevant permits and licences to ensure continuity. These same permits have the potential to support ColoSTAT® and other Rhythm product programs in the near future.

Digital Assets

An important asset contained within the Genetype acquisition is the historical patient clinical and genomic data. Following a process to ensure compliance with Federal, State and Territory privacy legislation, Rhythm is now the legal custodian of the entire Genetype dataset. The completion of this data transfer meets the requirements for the final completion of the Sale Agreement.

Physical Assets

The Genetype transaction was relatively light on physical assets but those assets representing value have been transferred to Rhythm's facilities in Melbourne, Australia and Charlotte, N.C., USA.

The full integration is anticipated to complete well ahead of the planned schedule and the coming weeks will see completion of the transfer of research projects, remaining partnership contracts and the final transfer of administrative services and a final update will be provided in due course. The Company is now focused on accelerating commercial growth of the geneType™ product portfolio in existing customer segments and is looking forward to expanding both the geographical footprint and portfolio breadth.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.